EP2: A Changing Drug Development Paradigm

Automation? Personalized medicine? A shifting talent pool? Dive into the rapidly changing world of drug development and listen to experts give their boldest predictions for the future of CROs. Host Lisa Sanford is joined by colleagues from Altasciences, Marie-Hélène Raigneau, CEO; Steve Mason, Co-COO; and Dr. Gaetano Morelli, Executive Vice President Medical Affairs and Chief Medical Officer; as they take a wide-angle look at the forces reshaping drug development today and predict what’s coming next for CROs, sponsors, and patients. From emerging AI applications to organ-on-a-chip technology, shifting talent dynamics, changes in day-to-day operations, and the possible rise of personalized medicine, their discussion explores how innovation is unfolding across the industry. About Off-Label With Altasciences: Off-Label presents candid conversations about the drug development industry from an insider perspective. We discuss trending topics and new developments alongside industry experts. Whether you’re drug development-curious or a seasoned veteran, enjoy as we peel back the label.